NCT04128462View on ClinicalTrials.gov

MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

November 30, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

July 31, 2025

Conditions

Hepatic Encephalopathy

Interventions

DRUG

MNK-6105

L-Ornithine Phenylacetate for IV infusion

DRUG

Placebo

Matching placebo for IV infusion

DRUG

Standard of Care

Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.